Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers *in vivo* and impacts viability and proliferation *in vitro*

Supplementary Figure 1

Immunohistochemical analyses were performed applying the rabbit anti-K23 antibody in a 1:600 dilution to a tissue microarray with various human tumors from different organ sites and matching or non-matching normal tissues (100 x magnification).

a)-f) K23 is upregulated in adenocarcinomas compared to normal mucosa from the same organ. a) normal pancreas (exocrine only); b) pancreas adenocarcinoma; c)-f) gastrointestinal adenocarcinomas of the c) stomach d) small intestine e) colon and f) rectum

g) normal prostate ; h) prostate adenocarcinoma; i) normal urothelium j) bladder transitional cell carcinoma grade II; k) normal endometrium; l) adenocarcinoma of the endometrium.

g)-l) K23 is not differentially expressed in epithelial cells of the prostate, bladder or uterus.

g)-1) K23 is not differentially expressed in epithelial cells of the prostate, bladder or uterus. g) normal prostate ; h) prostate adenocarcinoma; i) normal urothelium j) bladder transitional cell carcinoma grade II; k) normal endometrium; l) adenocarcinoma of the endometrium.





Supplementary Figure 2

Confocal microscopy of COS7 cells overexpressing *KRT23***.** Cells were labeled with the polyclonal rabbit anti-K23 antibody, applied in a 1:600 dilution. K23 expression (green) was visualized applying a 1:2000 dilution of the secondary antibody AlexaFlour 488 goat anti-rabbit IgG highly cross-adsorbed. (Leica DMRS confocal microscope, 63x, 2x zoom; Z-stack, 0.5m interval)



Supplementary Figure 3

Supervised Cluster analyses. Heatmap of the top 371 transcripts separating tumor with status "MSShigh Keratin23" and "MSI-low/no Keratin 23" as identified by immunohistochemistry followed by supervised clustering of transcript profiling data. Genes with a p-value < 0.05 in a SAM analysis and with a variance across all samples >0.5 were clustered using Cluster and Treeview (Eisen). Red are upregulated and green are downregulated genes.



Supplementary Figure 4

Ingenuity pathway analyses (IPA5.0). Transcript profiling data (U133plus2.0) from 10 normal colon mucosas were compared to those from 118 MSS and 35 MSI colon adenocarcinomas as well as to colon cancer cell lines SW480, CaCo2 (MSS) and HCT15, HCT116 (MSI). *KRT23, CEL, DACH1, CEBPB, TGIF2, SERPINE/2 and NOTCH1* were upregulated in MSS tumors, while *TFAP2a* and *NFIC* were upregulated in MSI tumors. Expression patterns of *KRT23* and *CEBPB* (MSS) and *TFAP2a* and *NFIC* (MSI) are reproducible in the cell lines analyzed.



Supplementary Table 1

Transcript profiling of seven keratins. Expression profiling of 122 colon samples using HG-U133A2.0 arrays and of 163 colon samples using HG-U133plus2.0 arrays shows strong significant upregulation of *KRT23* in MSS tumors compared to low transcript levels in MSI tumors and normal colon mucosa. Genome wide profiling identified only six other keratins to be differentially expressed in colon adenocarcinomas compared to normal mucosas. Extremely high expression of a keratin restricted to MSS tumors is thus a unique feature for *KRT23*. Median transcript signal, SD and fold change (FC) are given as log2 values.

		Nor	Normal MSS MSI		SI	N vs MSS		N vs MSI		MSS vs MSI			
Probe set	Symbol	mediar	n sd	mediar	n sd	mediar	n sd	FC	р	FC	р	FC	р
HG-U133A2.0 array		n=17		n=67		n=38							
218963_s_at	KRT23	5.6	0.2	7.6	1.4	5.5	0.7	1.4	4.8E-18	1.0	6.4E-01	0.7	4.1E-16
HG-U133Plus2.0 array		n=	n=10 n=118		n=35								
218963_s_at	KRT23	2.3	0.16	8.0	3.12	2.8	2.37	3.4	9.9E-35	1.2	3.3E-04	0.3	1.2E-09
213680_at	KRT6B	2.1	0.06	3.9	2.63	3.3	2.48	1.9	1.2E-18	1.6	1.5E-05	0.8	3.8E-01
209016_s_at	KRT7	2.9	0.14	3.2	0.87	3.8	1.45	1.1	2.8E-07	1.3	1.6E-06	1.2	9.4E-04
207811_at	KRT12	3.8	1.31	2.5	0.62	2.5	0.48	0.7	6.4E-03	0.6	5.4E-03	1.0	6.9E-01
212236_x_at	KRT17	4.6	0.26	5.6	1.47	5.4	1.51	1.2	1.1E-10	1.2	4.6E-05	1.0	8.8E-01
213953_at	KRT20	13.9	0.45	11.7	1.99	11.2	2.76	0.8	9.7E-16	0.8	2.5E-08	1.0	1.4E-01
220267_at	KRT24	4.9	0.88	2.6	0.34	2.6	0.46	0.5	3.3E-05	0.5	2.4E-05	1.0	8.1E-01

Supplementary Table 2

Top 17 genes (top 18 probe sets) differentially expressed between MSS tumors with high

Keratin23 and MSI tumors with low Keratin 23 as identified by immunohistochemistry followed by supervised clustering of transcript profiling data. Ratios are given as normalized ratio log2 (-INF, -1] and [1, +INF).

			normali: log2 (-IN [1, 1	zed ratio F, -1] and ·INF)	median log2			MSS vs MSI
			L *,		N	MSS	MSI	
Probe Set ID	Gene	Gene Title	MSS-N	MSI-N	n=17	n=21	n=18	p value
218963_s_at	KRT23	keratin 23 (histone deacetylase inducible)	2.1	-0.1	5.6	7.7	5.6	1.6E-07
221031_s_at	APOLD1	apolipoprotein L domain containing 1	1.8	-0.2	6.6	8.3	6.4	2.6E-05
218704_at	RNF43	ring finger protein 43	2.4	0.5	7.2	9.7	7.7	1.9E-08
218353_at	RGS5	regulator of G-protein signalling 5	0.2	-1.5	6.9	7.1	5.3	4.9E-07
218002_s_at	CXCL14	chemokine (C-X-C motif) ligand 14	1.1	-2.2	8.7	9.8	6.5	7.1E-08
217875_s_at	TMEPAI	transmembrane, prostate androgen induced RNA	1.6	0.0	6.7	8.3	6.6	6.9E-06
209049_s_at	PRKCBP1	I protein kinase C binding protein 1	0.9	-0.6	7.2	8.1	6.6	5.1E-08
208121_s_at	PTPRO	protein tyrosine phosphatase, receptor type, O	2.4	0.2	6.0	8.3	6.2	6.3E-07
207457_s_at	LY6G6D	lymphocyte antigen 6 complex, locus G6D	1.6	-0.1	6.4	8.0	6.3	2.8E-06
206286_s_at	TDGF1	teratocarcinoma-derived growth factor 1	2.0	0.2	6.2	8.2	6.5	6.0E-09
206108_s_at	SFRS6	splicing factor, arginine/serine-rich 6	0.0	2.4	6.3	6.3	8.8	9.9E-12
205910_s_at	CEL	carboxyl ester lipase (bile salt-stimulated lipase)	1.8	-0.1	5.3	7.1	5.3	1.7E-05
205471_s_at	DACH1	dachshund homolog 1 (Drosophila)	1.4	0.0	5.5	7.0	5.5	1.2E-06
205242_at	CXCL13	chemokine (C-X-C motif) ligand 13	-1.8	-0.3	6.9	5.1	6.7	8.8E-06
204070_at	RARRES3	retinoic acid receptor responder 3	-1.1	1.0	8.5	7.4	9.5	4.7E-09
203896_s_at	PLCB4	phospholipase C, beta 4	1.6	0.1	5.1	6.7	5.2	3.9E-08
201369_s_at	ZFP36L2	zinc finger protein 36, C3H type-like 2	0.4	-1.5	8.1	8.5	6.6	1.3E-05
201367_s_at	ZFP36L2	zinc finger protein 36, C3H type-like 2	1.2	-0.7	5.9	7.1	5.2	2.0E-05

Supplementary Table 3

Transcript profiling of 16 TFs potentially targeting *KRT23* **monitored on 163 tissue samples**

(U133plus arrays). Signal values are given as median log 2. Seven TFs with significant differences between MSS and MSI tumors with regard to the p value and the expression level are indicated with an asterisk. Three TFs, CEBPA, CEBPB and FOXQ1, shown in bold letters were regarded as highly relevant.

				median log2 signal			p value		
ID	Gene		Chr	N (n=10)	MSS (n=118)	MSI (n=35)	N ∨s MSS	N ∨s MSI	MSS ∨s MSI
204039_at	CEBPA	 CCAAT/enhancer binding protein (C/EBP), alpha 	19q13.1	8.03	8.46	7.61	8.00E-02	1.90E-01	2.64E-05
212501_at	CEBPB	 * CCAAT/enhancer binding protein (C/EBP), beta 	20q13.1	9.26	11.11	10.66	5.18E-06	6.86E-05	4.87E-05
227475_at	FOXQ1	* forkhead box Q1	6p25	2.66	10.17	7.98	3.33E-33	2.20E-14	6.55E-06
202221_s_	εEP300	* E1A binding protein p300	22q13.2	7.76	7.39	7.66	5.28E-01	6.10E-01	3.21E-02
210446_at	GATA1	* GATA binding protein 1	Xp11.23	2.16	2.15	2.15	5.77E-01	1.56E-02	4.17E-02
209636_at	NFKB2	 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) 	10q24	3.32	4.07	4.10	1.13E-04	6.71E-07	1.08E-02
40569_at	ZNF42/MZF1	* Zinc finger protein 42 (myeloid-specific retinoic acid-responsive)	19q13.2- q13.4	6.89	7.07	7.68	8.85E-02	3.54E-03	5.50E-03
241612_at	FOXD3	forkhead box D3	1p32-p31	2.86	2.76	2.75	1.20E-01	8.21E-02	9.95E-02
209710_at	GATA2	GATA binding protein 2	3q21.3	5.29	4.86	4.88	1.58E-02	3.18E-02	7.34E-01
205038_at	IKZF1	IKAROS family zinc finger 1	7p13- p11.1	2.77	2.49	2.49	5.72E-02	3.13E-01	1.05E-01
209239_at	NFKB1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	4q24	8.21	7.48	7.71	2.24E-07	6.53E-04	7.89E-02
206035_at	REL	v-rel reticuloendotheliosis viral oncogene homolog (avian)	2p13-p12	2.34	2.33	2.32	2.31E-01	1.07E-01	5.06E-01
1569638_a	t SOX5	SRY (sex determining region Y)-box 5	12p12.1	2.35	2.34	2.34	3.96E-01	2.06E-01	3.52E-01
207893_at	SRY	sex determining region Y	Yp11.3	2.09	2.08	2.08	5.62E-02	3.49E-02	4.93E-01
205688_at	TFAP4	transcription factor AP-4 (activating enhancer binding protein 4)	16p13	4.26	4.50	4.37	6.44E-04	1.82E-02	6.21E-02
209338_at	TFCP2	transcription factor CP2	12q13	6.37	7.19	7.11	4.82E-05	6.16E-05	3.86E-01